

|   |                                  |               |
|---|----------------------------------|---------------|
| <b>LIST OF REFERENCES CITED BY APPLICANT</b><br>(Use several sheets if necessary) | 10271-021-999                    | 09/724,531    |
|   | APPLICANT<br>Young et al.        |               |
|   | FILING DATE<br>November 28, 2000 | GROUP<br>1641 |

### U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL |    | DOCUMENT NUMBER | DATE     | NAME          | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|----------|---------------|-------|----------|----------------------------|
| SBC               | DU | 6,537,809       | 3/25/03  | Brams         | —     | —        |                            |
|                   | DV | 6,096,551       | 8/1/00   | Barbas et al. | —     | —        |                            |
|                   | DW | 5,693,762       | 12/2/97  | Queen et al.  | —     | —        |                            |
|                   | DX | 5,585,089       | 12/17/96 | Queen et al.  | —     | —        |                            |
| ✓                 | DL | 5,939,068       | 8/17/99  | Brams et al.  | —     | —        |                            |

### FOREIGN PATENT DOCUMENTS

|     |    | DOCUMENT NUMBER | DATE    | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
|-----|----|-----------------|---------|---------|-------|----------|-------------|
|     |    |                 |         |         |       |          | YES NO      |
| SBC | DY | WO 00/29584     | 5/25/00 | PCT     | —     | —        |             |
| SBC | DM | WO 96/05229     | 2/22/96 | PCT     | —     | —        |             |

### OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

|     |    |  |
|-----|----|--|
| SBC | DZ | Anderson et al., 1985, "Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay," J. Clin. Microbiol. 22:1050-1052   |
|     | EA | Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312(5995):643-646  |
|     | EB | Carson et al., 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311   |
|     | EC | Conrad et al., 1987, "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic," Pediatr. Infect. Dis. J. 6(2):152-158  |
|     | ED | Cruse et al., 1995, Illustrated Dictionary of Immunology, Boca Raton: CRC Press, pp. 18-19   |
|     | EE | Dorland's Illustrated Medical Dictionary, 1994, 28 <sup>th</sup> ed., Philadelphia: WB Saunders p. 874   |
|     | EF | Duenas et al., 1996, "In vitro immunization of naïve human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display," Immunology 89:1-7  |
|     | EG | Duenas et al., 1996, "Selection of phage displayed antibodies based on kinetic constants," Molecular Immunol. 33(3):279-285  |
|     | EH | Everitt et al., 1996, "The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers," J. Infect. Dis. 174:463-469         |
|     | EI | Foote et al., 1995, "Kinetic and affinity limits on antibodies produced during immune response," Proc. Nat'l Acad. Science USA 92:1254-1256  |
|     | EJ | Foote et al., 1991, "Kinetic maturation of an immune response," Nature 352:530-532   |
|     | EK | Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149:3903-3913   |
|     | EL | Greenspan et al., 1999, "Defining epitopes: It's not as easy as it seems," Nature Biotechnology 17:936-937   |
|     | EM | Groves et al., 1987, "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybridoma 6(1):71-76  |
|     | EN | Hall et al., 1985, "Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease," JAMA 254(21):3047-3051   |
|     | EO | Hall et al., 1983, "Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study," N. Engl. J. Med. 308(24):1443-1447  |
|     | EP | Hall et al., 1975, "Nosocomial respiratory syncytial virus infections," N. Engl. J. Med. 293(26):1343-1346   |
| ✓   | EQ | Haynes et al., 2002, "Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection," J. Virol. 76(14):6873-6881 |

APR 21 2004  
 SBC  
 PATENT & TRADEMARK OFFICE

|    |  |
|----|--|
| ER | Johnson et al., 1999, "A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19," J. Infect. Dis. 180(1):35-40  |
| ES | Karlsson et al., 1997, "Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors," J Immunol. Meth. 200:121-133  |
| ET | Knappik et al., 2000, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides," J. Mol. Biol. 296:57-86  |
| EU | Liu et al., 1987, "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40  |
| EV | LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc. Natl. Acad. Sci. USA 86(11):4220-4224  |
| EW | Morrison et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207  |
| EX | Morrison et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA 81(21):6851-6855  |
| EY | Myszka et al., 1999, "Survey of the 1998 optical biosensor literature," J. Mol. Recog. 12:390-408  |
| EZ | Newman et al., 1992, "'Primitization' of recombinant antibodies for immunotherapy of human diseases: A Macaque/HuNab chimeric antibody against human CD4," Biotechnol. 10:1455-1460  |
| FA | Prince et al., 1996, "Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid," J. Infect. Dis. 173:598-608   |
| FB | Raman et al., 1992, "Diffusion-limited rates for monoclonal antibody binding to cytochrome," Biochem. 31:10370-10379   |
| FC | Roost et al., 1995, "Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity," PNAS USA 92:1257-1261  |
| FD | Rosok et al., 1995, "A combinatorial library strategy for the rapid humanization of anticarcinoma BR 96 Fab," JBC 271(27):22611-22618  |
| FE | Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA 79(6):1979-1983   |
| FF | Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J. Immunol. 137(3):1066-1074   |
| FG | Schier et al., 1996, "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site," J. Mol. Biol. 263(4):551-567  |
| FH | Stemplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," Proc. Natl. Acad. Sci. USA 85(13):4852-4856   |
| FI | Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," Proc. Natl. Acad. Sci. USA 84(1):214-218   |
| FJ | Takeda et al., 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):452-454  |
| FK | Talwar et al., 1976, "Isoimmunization against human chorionic gonadotropin with conjugates of processed beta-subunit of the hormone and tetanus toxoid," Proc. Natl. Acad. Sci. USA 73(1):218-222  |
| FL | van Wyke et al., 1985, "Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus," Virology 143(2):569-582   |
| FM | Wald et al., 1988, "In re ribavirin: a case of premature adjudication?" J. Pediatr. 112(1):154-158   |
| FN | Wright et al., 1982, "Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children," Infect. Immun. 37(1):397-400  |
| FO | Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an avb-specific humanized mAb," PNAS 95:6037-6042  |
| FP | Geneseq Database, Accession no: AAW70933, entry date Oct. 1998 from patent no FR2758331-A1 of Bourgeois et al.   |
| DN | Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24   |
| DO | Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45  |
| DP | Landry et al., "Evaluation of reconstituted lyophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Infect. Dis. 166A: 969  |
| DQ | Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non-HIV virology, Intersci. Conf. Antimicrob. Agents Chemother. Toronto |
| DR | Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in high risk infants," Poster session infect. dis. 130A:768   |
| DS | Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976  |
| DT | Sorbera et al., 1998, "Palivizumab," Drug Data Report 20:702-703   |

EXAMINER

Hay B. Chen

DATE CONSIDERED

May 21, 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.